Index

Page numbers in *italics* denote figures; those in **bold**, tables.

abscesses
- FBA associated with, 290, 291
- subperiosteal orbital, 171

acid-base balance, and pulmonary function, 22–24

acidosis
- metabolic, 23
- respiratory, 23

active cycle of breathing technique (ACBT)
- for airway clearance, 276
- in cystic fibrosis, 231

activity, in airway obstruction, 138

acute respiratory distress syndrome (ARDS), 121

age-appropriate signs and symptoms of, 128
defined, 123

treatment of underlying conditions with, 123

acute respiratory problems
- foreign body aspiration, 286–292
- pneumothorax, 292–300
- respiratory failure, 300–309

adenoïdectomy, 170

“adenoid facies,” 253

adenoids
- assessment of, 253
- regrowth of, 259

adenotonsillar hypertrophy, and OSA, 249

adenotonsillectomy
- for childhood OSA, 258–259
- complications of, 259
- postoperative complications, 264

adenovirus, 113

ADHD, OSA symptoms mimicking, 258

adherence
- to asthma action plan, 213
- CPAP, 263

adventitious sounds, 48

aerobic exercise, in cystic fibrosis, 231

afrin/neosynephrine, for sinusitis, 168

air-blood barrier, 12

airflow, in diagnosis of OSA, 255
airflow obstruction
  in asthma, 195–196
during sleep, 250
airway. See also lower airway
diseases
  divisions in, 7, 8, 9
  obstruction in, 135
  in OSA, 249
pediatric
  anatomy and physiology of, 132–135, 133
  compared with adult, 133, 134
  transfer of gases through, 9–11,
  10
types of, 6, 8
airway assessment, 135–139
  diagnostic imaging in, 138–139
  endoscopy in, 138
  history in, 136
  physical examination in, 136–138
airway clearance
  in bronchiectasis, 281
  in cystic fibrosis, 229–231
  in PCD, 276–277
airway clearance therapy, 229–230
  active cycle of breathing
  technique, 231
  airway oscillating devices, 231
  chest physical therapy, 230
  exercise, 231
  high-frequency chest
  compression, 231
  positive expiratory pressure
  (PEP) therapy, 230–231
airway obstruction
  Mallampati classification of, 253
  management of, 241
  airway oscillating devices, in cystic
  fibrosis, 231
  airway problems, in respiratory
  health history, 42
albuterol aerosol therapies, in
  bronchiolitis, 117
albuterol nebulization, heliox-
  driven, 210
albuterol sulfate, during asthma
  exacerbation, 31
albuterol syrup, 52
alkalosis
  metabolic, 23
  respiratory, 23
allergies
  and asthma symptoms, 207
  in respiratory health history, 39
allergy testing
  in asthma, 202
  in sinusitis, 167
altitude, acclimatization to, 13,
  13–15
alveolar epithelial cells
  type I, 29–30
  type II, 30
alveolar surface, conditions
  decreasing, 15
alveoli
  embryology of, 4
  formation of, 9
  in gas exchange, 10–11
ambu-bag-mask assembly, 308
American Academy of Pediatrics
  (AAP)
  on antibiotic use, 111
  on OSA, 263
  polysomnography recommended
  by, 264
Subcommittee on Management
  of Sinusitis of, 166
American Academy of Pediatrics
  Guidelines, on medication
  for sinusitis, 168
American Thoracic Society (ATS),
  196, 264
amniotic fluid, 4
amoxicillin, in sinusitis, 167
anterior axillary lines, 43
antibiotic resistance, 129
antibiotics
  in bronchiolitis, 117
  in bronchitis, 125
  in chronic sinusitis, 170
  in cystic fibrosis, 232
antibiotics (cont’d)
overuse of, 114
for PCD, 275–276
in pneumonia, 123
prophylactic, 275
in sinusitis, 167–168
antibiotics, inhaled
adverse effects associated with, 72
and bronchiectasis, 281
in cystic fibrosis, 228–229
formulations for, 73
generic and brand names for, 73
indications for, 72
mechanism of action for, 71
anticholinergics
adverse effects associated with, 57
in asthma, 205
formulations for, 58
generic and brand names for, 58
indications for, 57
mechanism of action of, 56–57
anticholinergic sprays, in chronic
sinusitis, 170
anticipatory guidance
age-appropriate, 42
for asthma, 214
for bacterial tracheitis, 128–129
in bronchiectasis, 281–282
for pneumonia, 124
for RSV bronchiolitis, 118–119
antihistamines
in chronic sinusitis, 170
in rhinitis, 179
in sinusitis, 169
antihistamines, first-generation
adverse effects associated with, 68
formulations for, 68
generic and brand names for, 68
indications for, 68
mechanism of action for, 68
anti-inflammatory medications, in
cystic fibrosis, 229
apnea
in bronchiolitis, 116
identification of, 89
triggers for, 90
apnea-hypopnea index (AHI), 257
apnea monitor, 88
apnea of prematurity
complications of, 88
diagnosis of, 87–88
epidemiology of, 86
in infants, 85
management of, 88–89
methylxanthines, 90
nursing care in, 89–91
parents and, 91
pathophysiology of, 86–87
signs and symptoms of, 87
types of, 87
apneic episode
assessment of, 89, 91
documentation of, 90
intervention for, 90
apneustic center, in control of
ventilation, 36
appetite, in cystic fibrosis, 223
Arnold-Chiari malformation, 142,
144
arterial blood gases (ABGs), 94
in bronchiolitis, 116
in respiratory failure, 305–306
arteries, formation of, 9
arthralgia, omalizumab associated
with, 65
articulation, 134
aspirin sensitivity, and asthma
symptoms, 207
assist control (AC) mode, for
mechanical ventilation, 307
asthma
albuterol sulfate in, 31
assessing severity of, 202
bronchiolitis and, 115
complications of, 203
control of, 200–201
defined, 188


and environment, 191

epidemiology of, 189–191

exercise-induced, 194

genetics of, 190–191

history for, 194–195

information resources for, 214–215

leukotriene modifiers for, 62

management of, 204

allergen avoidance, 204–205

exacerbations, 208–210

monitoring control, 207–208

pharmacotherapy, 205–207

stepwise approach, 205–206

natural history of, 189, 190

nursing care in, 210

allergen/trigger avoidance, 211

anticipatory guidance, 214

barriers to care, 213

explaining basic facts, 211

follow-up care, 215

providing information about medications, 211–212

teaching self-management, 212–213

pathophysiology of, 191–194

phenotype of, 194

physical examination in, 195

and rhinitis, 180

severity classification for, 198–199

severity of, 198–199, 203

signs and symptoms of, 194–195, 206–207

step therapy for, 198–199

and wheezy bronchitis, 125

asthma action plan, 212–213, 213

asthma educators, national certification for, 210

Asthma Predictive Index, 125

atelectasis, in FBA, 290, 291

augmentin, for sinusitis, 168

auscultation, in respiratory

physical examination, 48

azoospermia, in cystic fibrosis, 223

aztreonam lysine, 71–72, 73

back blows, in foreign body aspiration, 291, 292

bacterial infection

clinical features in, 111

in cystic fibrosis, 225–226

in lower airway respiratory disease, 114, 114–115

bacterial tracheitis, 110

complications with, 128

diagnosis of, 128

epidemiology of, 127

nursing care in, 128–129

pathophysiology of, 127

treatment for, 128

balloon laryngoplasty, in subglottic stenosis, 151

barium esophagrams, 139

beclomethasone, 60

behavioral deficits, and OSA incidence, 258

behavior changes, leukotriene modifier use associated with, 62

\( \beta_2 \)-agonists

anti-inflammatory effects of, 52

synthetic production of, 52

\( \beta_2 \)-agonists, long-acting

adverse effects associated with, 55–56

formulations for, 56

generic and brand names for, 56

indications for, 54–55

mechanism of action for, 54

\( \beta_2 \)-agonists, short-acting

adverse effects of, 53

formulations for, 54

generic and brand names for, 53–54

indications for, 52

mechanism of action of, 51–52
\( \beta_2 \) antagonist receptor (\( \beta_2 \)AR), in asthma, 190–191
bilevel positive airway pressure (BiPAP), in respiratory failure, 306–307
birth history, 41–42
blebs, subpleural, 294
bleomycin, impact on alveolar surface of, 15
blood-brain barrier (BBB), 33
blood pressure. See also hypertension
impact of OSA on, 254
in respiratory failure, 305
blowing games, for airway clearance, 276
Bohr effect, 21
brain stem, in control of ventilation, 35
breathing
control of, 32
muscles of, 28, 28–29
expiration, 29
inspiration, 28, 28–29
normal, 25, 35–36
breathing patterns, 45, 46
breath sounds, and OSA, 253
bronchi, embryology of, 4
bronchial hyperresponsiveness (BHR), 189
bronchial tree, embryology of, 4, 5
bronchiectasis
complications with, 281
defined, 274
diagnosis of, 280–281
epidemiology of, 279
FBA associated with, 290, 291
nursing care in, 281–282
pathophysiology of, 280
PCD associated with, 269, 272, 274–275
signs and symptoms of, 280
treatment of, 281
bronchioles, embryology of, 4, 5
bronchiolitis, 110
in BPD, 97
complications with, 116–117
diagnosis of, 116
epidemiology of, 115
management of, 117–118
nursing care in, 118–119
pathophysiology of, 116
signs and symptoms of, 116
bronchitis, 110
categories of, 125
complications with, 126–127
in cystic fibrosis, 223
epidemiology of, 125
nursing care for, 127
pathophysiology of, 126
signs and symptoms of, 126
bronchoconstriction
exercise-induced, 194
irritants stimulating, 33, 35
prevention of exercise-induced, 62
bronchodilators, 99
anticholinergics
adverse effects associated with, 57
formulations for, 58
generic and brand names for, 58
indications for, 57
mechanism of action of, 56–57
in BPD, 96
in cystic fibrosis, 227
long-acting \( \beta_2 \)-agonists
adverse effects associated with, 55–56
formulations for, 56
generic and brand names for, 56
indications for, 54–55
mechanism of action for, 54
short-acting \( \beta_2 \)-agonists
adverse effects of, 53
formulations for, 54
generic and brand names for, 53–54
indications for, 52
mechanism of action of, 51–52
bronchophony, 49
bronchopleural fistula, 294
bronchoprovocation studies, in asthma, 197, 202
bronchopulmonary dysplasia (BPD)
complications associated with, 100
complications of, 95
diagnosis of, 94–95
discharge of infant with, 102–104, 103
epidemiology of, 91–92
established phase of, 101–102
evolving phase of, 98–101
in infants, 85
management of, 96–97
“new,” 93
nursing care of infant with, 97–104
pathophysiology of, 92–93
signs and symptoms of, 93–94
well child care needs of infant with, 104
bronchoscopy
in bronchiectasis, 281
for FB removal, 292
in laryngeal web, 152
in PCD, 277
in subglottic hemangioma, 154
in subglottic stenosis, 149
in tracheomalacia, 155–156
broncho/tracheal sounds, 48
bronchovesicular sounds, 48
budesonide, 60
budesonide, nebulized, 160
“bump beds,” 88

caffeine, in apnea of prematurity, 88–89, 90–91
candidiasis, inhaler use associated with, 59
carbon dioxide (CO₂), chronic retention of, 23
carbon dioxide (CO₂), partial pressure of (PCO₂), and
oxyhemoglobin dissociation curve, 17, 18
carbonic anhydrase, 20
carbon monoxide (CO), diffusion limited, 14
carboxyhemoglobin, in gas exchange, 19–22, 21
cardiac disease. See also heart disease
asthma associated with, 203
congestive heart failure, 15
cardiopulmonary arrest, 306
cardiopulmonary status, in pneumothorax, 300
cardiorespiratory monitoring, in respiratory failure, 308
cardiovascular system
impact of OSA on, 254
in respiratory failure, 304
Cayston (aztreonam lysine), 73
ceftriaxone, for sinusitis, 168
cellulitis, periorbital, 171
Centers for Disease Control and Prevention (CDC)
on antibiotic use, 111
on cough suppressants, 66
cerebrospinal fluid (CSF), 32, 33
buffering capacity of, 33
rhinorrhea, 175
“CF Core Self-Management Performance Objectives for Patients and Families–2010” (CFF), 240–242
CFTR modulation, in cystic fibrosis, 234–235
chemokines, in asthma, 193
chemoreceptors, in control of ventilation, 32–33, 34
chest compressions, in FBA, 291, 292
chest expansion, palpation of, 47
chest pain, in respiratory health history, 41
chest physical therapy (CPT)
in bronchiolitis, 117
in cystic fibrosis, 230
chest tightness
in cystic fibrosis, 226
in respiratory health history, 41
chest tube
insertion, 299
managing and monitoring, 299
milking or stripping, 299–300
placement, 298
chest wall
of infants, 85
in OSA, 261
pediatric, 45
in respiratory failure, 304
chest wall oscillation therapy,
high-frequency, in PCD, 276
chest X-ray
in asthma, 197
in bronchiolitis, 116
in bronchitis, 126
in diagnosis of pneumothorax, 296, 297
in foreign body aspiration, 289–290, 290
pneumothorax on, 123
in recurrent pneumonia, 124
children, younger, respiratory
system in, 300
Chlamydia pneumoniae, in lower
airway disease, 114, 114
chloride channel activators, in
cystic fibrosis, 233
choanal atresia, 175
choking, in foreign body
aspiration, 288
Churg-Strauss syndrome, 62
ciliary dyskinesia. See primary
ciliary dyskinesia
cilium, respiratory
270, 271
circulation
fetal, 6, 7, 7–8
postnatal, 6, 7
clubbing, of nail beds, 45–46, 47
cockroach exposure, and asthma
symptoms, 204–205
codeine
adverse effects associated with, 67
formulations for, 68
generic and brand names for, 67–68
indications for, 67
mechanism of action for, 67
colistimethate sodium, 71–72, 73
Coly-Mycin M (colistimethate
sodium), 73
common cold
epidemiology of, 163–164
treatment of, 178
community-acquired pneumonia
(CAP) or nosocomial
pneumonia, 119, 120
complementary therapies, for
sinusitis, 169
compliance, lung, in BPD, 93
computed tomography (CT)
in airway assessment, 139
of chest, 291
for orbital complications of
sinusitis, 171
in sinusitis diagnosis, 166–167
congenital bilateral absence of vas
derefers (CBAVD), in cystic
fibrosis, 223
congestive heart failure, and
alveolar surface, 15
consolidation
on chest X-ray, 94
percussion of, 49
contact isolation precautions,
in RSV bronchioloitis,
118
continuous positive airway
pressure (CPAP), 88
advantages and disadvantages
of, 262
in ARDS, 123
in BPD, 96
monitoring use of, 263
in OSA, 261, 262
in respiratory failure, 306–307
corticosteroids
after mechanical ventilation, 96
anti-inflammatory effects of, 58
in asthma, 203, 205
in children with croup, 159
in exacerbations of asthma, 209
in OSA, 260
overuse of, 146
prolonged use of, 98
corticosteroids, inhaled
adverse effects associated with, 59–60
in cystic fibrosis, 229
formulations for, 60
generic and brand names for, 60
indications for, 59
mechanism of action for, 58–60
cough
with allergic rhinitis, 177
anatomy of, 134
asthma, 194
“barky,” 158
in bronchitis, 125
in cystic fibrosis, 223
in foreign body aspiration, 288, 289
“huff,” 230
in pleural effusion, 122
in respiratory health history, 40
in sinusitis, 166
cough suppressants
codeine, 67–68
dextromethorphan, 66–67
CPAP. See continuous positive airway pressure
crackles, in respiratory failure, 304
crepitus
causes of, 46–47
in pneumothorax, 295–296
cricoid split, 151
cromolyn
adverse effects associated with, 64
in asthma, 205
formulations for, 64
generic and brand names for, 64
indications for, 64
mechanism of action of, 63–64
croup, 149, 154, 157–160. See also
laryngotracheobronchitis
cry, in airway obstruction, 137, 137–138
cyanosis, in respiratory failure, 305
cystic fibrosis care centers, 243
cystic fibrosis (CF)
complications of, 225–227
developmental stages in, 239, 240
diagnosis of, 224–225
incidence of, 221
management of
emerging therapies, 233–235
gastrointestinal management, 232–233
pulmonary management, 227–232
nursing care in, 235
adherence issue, 238–239
daily management plan, 237
education, 239–241, 240
health maintenance, 238
infection control, 236
obtaining health history, 235–236
physical examination, 236
preventive care, 237
pathophysiology of, 221–222
signs and symptoms of, 222–224
Cystic Fibrosis Foundation (CFF) Registry, 221
Cystic Fibrosis Foundation Patient Education Committee, 240
cystic fibrosis liver disease (CFLD), 227
cystic fibrosis-related diabetes mellitus (CFRD), 227
cystic fibrosis transmembrane conductance regulator (CFTR), 222
cytokines, in asthma, 192–193
daily weights, for infant with BPD, 101
death, FBA associated with, 291.  
See also mortality
decongestants, nasal, for sinusitis, 168
decongestants, oral  
adverse effects associated with, 70  
formulations for, 71  
generic and brand names for, 70  
indications for, 70  
mechanism of action of, 69–70  
decongestants, topical, 71  
delivery devices  
advantages and disadvantages of, 75  
DPIs, 73, 74, 76, 77  
holding chambers, 76, 77–78  
MDIs, 73, 74, 76  
nebulizers, 76, 77  
reviewing technique for, 215  
dendritic cells, in asthma, 192  
denufosol, in cystic fibrosis, 233  
deoxyhemoglobin, 20  
*Dermatophagoides pteronyssinus*, 204  
developmental delay, risk of, 104  
developmental levels in cystic fibrosis, 239, 240  
and physical examination, 38–39  
dexamethasone, for children with croup, 159–160  
dextromethorphan  
adverse effects associated with, 66  
formulations for, 67  
generic and brand names for, 67  
indications for, 66  
mechanism of action of, 66  
diaphragm, assessment of, 49  
diffusion  
defined, 11  
in transfer of gas in parenchyma, 11–15  
dilation, in subglottic stenosis, 151  
dipalmitoyl phosphatidylcholine (DPCC), 30  
diphenhydramine, 68  
2,3-diphosphoglycerate (2,3-DPG), in oxygen delivery, 14  
discharge instructions, in bronchiolitis, 118–119  
discharge preparation, for infant with BPD, 102–104, 103  
distal intestinal obstructive syndrome (DIOS), in cystic fibrosis, 226. See also meconium ileus  
diuretics  
administration of, 98–99  
in BPD, 96  
DNA testing, for cystic fibrosis, 224  
dornase alfa, in cystic fibrosis, 228  
dry-powder inhalers (DPIs), 73, 74, 76, 77  
optimal technique for, 74  
teaching use of, 212  
technique for using, 73  
dust mites (DMs)  
and allergic rhinitis, 174  
and asthma symptoms, 204  
education. See also nursing care about asthma, 210–211  
for children with rhinitis, 180  
about cystic fibrosis, 239–241, 240  
about epiglottitis, 162  
about FBA prevention, 292  
in PCD, 279  
about pneumothorax, 300  
education plan, cystic fibrosis, 240  
egogony, 49  
electromyogram, in sleep studies, 254  
elevations, acclimatization to, 13, 13–15  
embryology, of respiratory system, 3–4, 5, 6, 7–8  
emergency evacuation of pleural air in, 298  
respiratory distress as, 300
emergency department visits, in respiratory health history, 42
emphysema
and alveolar surface, 15
respiratory mechanics in, 26
encephalocele, and VCP, 142
endoscopic examination, 138
endoscopic sinus surgery, 170–171
endoscopy, nasal, 178
endotracheal tubes, 307
care of, 101
and subglottic stenosis, 149–150
suctioning of, 309
end tidal CO₂ in respiratory failure, 308
enteral feedings, for infants with BPD, 102
enuresis, and OSA, 252
environment
and asthma development, 191
in respiratory health history, 42
environmental avoidance strategies, 178
enzyme-linked immunosorbent assay (ELISA), for rhinitis, 177
eosinophils, in asthma, 192
epiglottitis
complications of, 162
epidemiology of, 160–161
management of, 161
nursing care for, 162
pathophysiology of, 161
signs and symptoms of, 161
equipment, cleaning and disinfecting, 237
Erasistratus, 3
erythropoietin (EPO), 13
Escherichia coli, pneumonia caused by, 120
esophagoscopy, 156
ethmoid sinuses, 163
ethnicity, and asthma incidence, 189
ET tubes. See endotracheal tubes
exacerbations of asthma, managing, 208–210
exercise
for airway clearance, 276
and alveolar surface, 15
exhalation, mechanics of, 25, 25
Expert Panel Report (EPR), of NAEPP, 188
Expert Panel Report 3 (EPR3), 188–189, 197, 207
expiration, muscles of, 28, 29
extracellular fluid (ECF), 32
extracorporeal membrane oxygenation (ECMO), 308
extubation, in respiratory health history, 42
eyes, effect of corticosteroids on, 60
face mask, used with MDIs, 75
failure to thrive, in cystic fibrosis, 223
families
of child with chronic sinusitis, 173
in rhinitis care, 180
and stress of hospitalizations, 156–157
families, teaching. See also education
in bronchiectasis, 282
about cystic fibrosis, 239–241, 240
in PCD, 279
family assessment, in RSV bronchiolitis, 118
family history, in asthma, 195
family size, and asthma incidence, 190
fat-soluble vitamins, in cystic fibrosis, 223
fatty acid deficiency, in cystic fibrosis, 223
feeding. See also nursing care
of infants with apnea of maturity, 91
of infants with BPD, 94
and nursing care, 101
with VCP, 143
fertility issues, PCD associated with, 272, 278
FEV₁, in exacerbations of asthma, 209
FEV₁/FVC ratio, 202–203
Fick’s law, 11–13, 12, 14
flunisolide, 60
fluoroscopy, 139, 156
fluticasone, 60
follow-up care
  for asthma patients, 207, 215
  for infants with BPD, 103
Food and Drug Administration (FDA)
on cough suppressants, 66
labeling requirements of, 55
on medication for sinusitis, 167–168
forced expiratory volume in 1 second (FEV₁), 79
  in PCD, 273
  in spirometry, 196
forced vital capacity (FVC), in
  spirometry, 196
foreign bodies, laryngotracheal, 287
foreign body aspiration (FBA)
  complications of, 291
  diagnosis of, 194, 289–291, 290
  epidemiology of, 286–287
  management of, 291
  nursing care in, 292
  pathophysiology of, 287
  risk factors for, 292
  signs and symptoms of, 287–288
  medical history in, 288
  physical examination in, 288
formoterol, 54–55, 55
fremitus, tactile, palpation for, 47
frontal sinuses, 163
functional endoscopic sinus
  surgery (FESS), 170
functional residual capacity (FRC), 25, 26, 87
funnel chest (pectus excavatum), 43, 45
furosemide, 98–99
gas exchange
  chemical reactions during, 21
  transfer through airways, 9–11, 10
gastroesophageal reflux disease (GERD), 104
  asthma associated with, 203
  and asthma symptoms, 207
  in BPD, 95, 97, 101
chronic sinusitis associated with, 165
diagnosis of, 194
  and laryngomalacia, 141
  and sinusitis, 170
gender, and asthma incidence, 189
gene therapy, in cystic fibrosis, 235
genetic disorder, asthma as, 190–191
genetics, of cystic fibrosis, 221–222
genetic testing, in PCD, 273
Genome-wide association studies (GWAS), 190
glottis, 132
glucocorticoid therapy, antenatal, 30
gram-negative enteric bacilli, pneumonia caused by, 120
Group B B-hemolytic streptococci (GBS), pneumonia caused by, 120
growth
  effect of corticosteroids on, 60
  impact of OSA on, 254, 256
  growth hormone secretion, 256
guaifenesin, properties of, 69
Guidelines for the Diagnosis and Management of Asthma, 55
Haemophilus influenzae
  in acute sinusitis, 165
  in lower airway disease, 114, 114
Haemophilus influenzae type B (Hib)
  in epiglottitis, 160
  pneumonia caused by, 120
  hand washing, 236
H2 antagonists, in cystic fibrosis, 233
head, assessment of, 45
head bobbing, in respiratory failure, 304
health-care services, utilizing, 241–242
hearing loss, PCD associated with, 278
heart disease, and OSA, 257. See also cardiac disease
heart rate, in respiratory failure, 305
Heimlich maneuver, in FBA, 291
heliox, in child with croup, 160
hemangioma
  of infancy, 153
  subglottic, 153, 153–154
heme, 15
hemoglobin (Hb), types of, 15
hemoglobinopathies, 303
hemoptysis
  in cystic fibrosis, 226
  in respiratory health history, 41
hemorrhage, alveolar, 15
Henderson-Hasselbach equation, 22–23
hepatic disease, in cystic fibrosis, 226–227
herbal therapies, for sinusitis, 169
Hib vaccine, 120, 160
high-altitude training,
  physiological principles of, 14
high-frequency chest compression (HFCC), in cystic fibrosis, 231
high-frequency ventilation (HFV), 307
history, medical, 38
  in asthma, 196
  in foreign body aspiration, 288
  in respiratory failure, 303
history, respiratory health
  chest pain in, 41
  chest tightness in, 41
  components of, 39
  cough in, 40
  hemoptysis in, 41
  shortness of breath in, 40–41
  sputum production in, 41
  wheezing in, 40
hoarseness, in foreign body aspiration, 289
holding chambers, 76, 77–78
hospitalization
  for asthma, 189
  for bronchitis, 127
  and family stress, 156–157
  for pneumonia, 123, 124
  rehospitalization, 95
in respiratory health history, 42
huffing, for airway clearance, 276
human metapneumovirus (hMPV), 114
human papillomavirus (HPV), 147
humidified mist, for children with croup, 159
hydrocephalus, 142, 144
hyoid bone, 133, 134
hyperactivity, and OSA, 253
hypercapnia
  in BPD, 93
  response of premature infants to, 86
hyperinflation, in FBA, 290–291
hypertension. See also pulmonary hypertension
  in BPD, 95
  in infants with BPD, 97
  OSA and, 257
hypopharynx, anatomy of, 133
hypothalamic-pituitary-adrenal axis, effect of corticosteroids on, 60
hypoxemia
  arousals from sleep versus, 250
  in BPD, 93, 96
  causes of, 302
  in low CO concentrations, 19
hypoxia
  anemic, 303
  classification of, 302
  in OSA, 257
  response of premature infants to, 86
iatrogenic insults, and subglottic stenosis, 149
ICSs
in asthma, 205
delivery of, 212
IgE, in asthma, 193
illnesses, in respiratory health history, 42
imaging, in PCD, 277. See also radiological evaluation
immunology testing, in asthma, 202
immunomodulators, in asthma, 205
immunotherapy, for allergic rhinitis, 180
impulsivity, OSA and, 253
In-Check DIAL, 78, 78, 79, 212
infants. See also newborns
respiratory problems in preterm, 85
respiratory system in, 300
infection control, for patient with cystic fibrosis, 236–237
infections
FBA associated with, 291
upper airway
epiglottis, 160–162
laryngotraeobronchitis (croup), 157–160
rhinitis, 162, 173–180
sinusitis, 162–173
inflammation
in asthma, 191–193, 202–203
biomarkers of, 202–203, 207
and OSA, 250
and subglottic stenosis, 149
influenza
asthma associated with, 203
bacterial superinfection in, 111
clinical presentation of, 112–113
diagnosis of, 113
immunization for, 127
incidence of, 112
treatment of, 113
influenza vaccine, 102, 113
inhalation, mechanics of, 25, 25
inhalers
dry-powder, 73, 74, 76, 77, 212
metered-dose, 52, 73, 74, 76, 212
minimum approved age for, 69
inspection, in respiratory physical examination, 43, 44, 45–46, 46
inspiration, muscles of, 28, 28
inspiratory-to-expiratory ratio (I:E ratio), 45
insulin, in cystic fibrosis, 233
interstitial fibrosis, respiratory mechanics in, 26
intubation, tracheal, 307. See also endotracheal tubes
ipratropium and albuterol, 58
ipratropium bromide, 57, 58
irrigations, daily sinus, 173
jaundice, neonatal, in cystic fibrosis, 226
J-receptors, in control of ventilation, 35
Kartagener’s syndrome (KS), 269, 270–272
kidney stones, in BPD, 95
KTP laser treatment, in subglottic stenosis, 151
laboratory evaluation, in respiratory failure, 305–306
laminar flow, 31
landmarks, thoracic, 43, 44
laryngeal chemoreflex, 86
laryngeal mask airway (LMA), 307
laryngeal webs, 151–152
laryngomalacia, 136
complications of, 141
diagnosis of, 140, 140–141
epidemiology of, 139
management of, 141
in OSA, 261
signs and symptoms of, 139–140
laryngopharangeal reflux, ruling out, 139
laryngoplasty, balloon, in subglottic stenosis, 151
laryngoscopy
to diagnose RRP, 148
to diagnose sinusitis, 167
epiglottitis on, 161
in laryngeal web, 152
in laryngomalacia, 140, 140–141
in subglottic stenosis, 150
in VCP, 143
laryngotracheal reconstruction, 151
laryngotracheobronchitis (croup)
complications of, 160
diagnosis of, 158
epidemiology of, 157–158
infectious, 149
management of, 158–160
pathophysiology of, 158
signs and symptoms of, 158
larynx
anatomy of, 132–134, 133
anomalies of
laryngeal webs, 151–152
laryngomalacia, 139–141, 140
subglottic hemangioma, 153, 153–154
subglottic stenosis, 148–151, 150
vocal cord disorders, 141–146
vocal cord masses and lesions, 146–147
innervations of, 134–135
role of, 134
laser excision, of vocal cord RRP, 148
laser treatment, in subglottic stenosis, 151
learning deficits, and OSA incidence, 258
leukodystrophy, and VCP, 142
leukotriene modifiers
adverse effects associated with, 62–63
in asthma, 205
formulations for, 63
generic and brand names for, 63
indications for, 61–62
mechanism of action for, 61
leukotriene receptor antagonists, in chronic sinusitis, 170
lip color, assessment of, 45
lobule of lung, microscopic anatomy of, 10, 10
long-acting beta agonists (LABAs), in asthma, 191, 205
lower airway diseases, 110–111
adenovirus, 113
bacterial, 114, 114–115
bacterial tracheitis, 127–129
bronchiolitis, 115–119
bronchitis, 125–127
human metapneumovirus, 114
influenza, 112–113
parainfluenza, 112
pneumonia, 119–124
RSV, 111–112
lung bud, formation of, 9
lung disease. See also specific disease
apnea of prematurity, 86–91
neonatal, 85
lung function
in PCD, 275
peak flow meters to assess, 79
lungs
and acid-base balance, 22–24
and airway resistance, 31
function of, 3
gases and gas exchange in
in parenchyma, 11–15, 13
in red blood cell, 15–22, 16, 18–21
through airways, 9–11, 10
growth in utero, 4
nongas exchange functions of, 9
regional differences of, 32
and respiratory mechanics, 24–26, 25, 27, 28
static properties of, 26, 28
surface tension properties of, 29–31
lungs sounds, 48
lungs therapeutics
  bronchodilators, 51–58
  cough suppressants, 66–68
cromolyn, 63–64
decongestants, 69–71
delivery devices for, 73, 74, 76
expectorants, 69
first-generation antihistamines, 68
inhaled antibiotics, 71–73
inhaled corticosteroids, 58–60
inhaler teaching device, 78, 79
leukotriene modifiers, 61–63
omalizumab, 64–65
lymphocytes, in asthma, 191–192
lymphoid hyperplasia, peak age of, 248
macrolide therapy, in cystic fibrosis, 229
macrophages, in asthma, 192
magnesium, intravenous, in asthma exacerbations, 210
magnetic resonance imaging (MRI) in airway assessment, 139
of chest, 291
Mallampati score, 253
mast cells, in asthma, 192
maternal preeclampsia, and development of BPD, 92
maternal smoking, and asthma incidence, 189
maxillary sinuses, 163. See also rapid maxillary expansion
meatus, 163
meconium aspiration syndrome, 293, 308
meconium ileus, in cystic fibrosis, 223, 226. See also distal intestinal obstructive syndrome
medication administration, teaching, 103
medications. See also lung therapeutics
  for allergy symptoms, 178–179
  in respiratory health history, 39
medulla, in control of ventilation, 35
metabolic acidosis, 23
metabolic alkalosis, 23
metaproterenol syrup, 52
metered-dose inhalers (MDIs), 73, 74, 76
  advantages and disadvantages of, 75
  albuterol, 52
  breath-activated, 73, 74
  levalbuterol, 52
  optimal technique for, 74
  teaching use of, 212
  technique for using, 73
methacholine challenge testing (MCT), 197
methicillin-resistant Staphylococcus aureus (MRSA), 129
methylxanthines
  in apnea of prematurity, 88–89
  in asthma, 205
  side effects of, 90
Mexico City Olympics, 14
midaxillary line, 43, 44
midclavicular lines, 43, 44
midsternal line, 43, 44
molecular analysis, in cystic fibrosis, 224
mometasone, 60
monitoring
  of apnea, 88
  in bronchiolitis, 118
  cardiorespiratory, 308
  in NICU, 87
montelukast (Singulair), 61, 63
Moraxella catarrhalis, in acute sinusitis, 165
morbidity
  CF-related, 222
  and OSA, 247
mortality
  of asthma exacerbations, 203
due to inhaled or ingested
  foreign bodies, 287
mouth breathing
  chronic, 177
  in epiglottitis, 161
mucolytic agents, for sinusitis, 168
Mucomyst® (acetylcysteine), 276
muscarinic acetylcholine receptor
  subtypes, 56–57
muscles
  of expiration, 28, 29
  of inhalation, 28, 28–29
laryngeal, 134
  pulmonary stretch receptors in, 33
  in respiratory failure, 304
muscular dystrophies, and VCP, 142
mutations, in cystic fibrosis, 222
Mycoplasma pneumoniae, in lower
  airway disease, 114, 114
myelomeningocele, and VCP, 142
nail beds
  assessment of, 45
  clubbing of, 45–46, 47
nasal cannula, for oxygen
  administration, 100
nasal cavity, anatomy of, 163
nasal decongestants, for sinusitis, 168
nasal discharge, in sinusitis, 165
nasal flaring
  in respiratory distress, 162
  in respiratory failure, 304
nasal lesions, granulomatous, 175
nasal mucosal biopsy, to diagnose
  sinusitis, 167
nasal potential difference (PD), in
cystic fibrosis, 224–225
nasal saline spray, for sinusitis,
  168–169

National Asthma Education and
  Prevention Program (NAEPP), 188
nebulization, drug wasted during,
  77
nebulizers, 76
  mechanism of, 77
  optimal technique for, 74
  types of, 76
neck extension, in epiglottitis, 161
needle aspiration, in
  pneumothorax, 298
neonatal intensive care unit
  (NICU)
  blood gases in, 94
  cardiorespiratory monitoring in, 87
neonates. See also newborns
  lung disease in, 85
  VCP in, 144
neoplasms, omalizumab associated
  with, 65
neurological examination, in
  respiratory failure, 304
neurological signs, in BPD, 96
neutrophils, in asthma, 192
newborns. See also neonates
  lung disease in, 85–91
  pneumothorax in, 293
  screening for cystic fibrosis of, 225
nitric oxide measurement, in PCD, 273–274
nonallergic rhinitis with
eosinophilia syndrome
  (NARES), 175, 178
nonsteroidal anti-inflammatory
drugs (NSAIDs), in
  pneumonia, 124
nursing care
  in apnea of prematurity, 89–91
  in bacterial tracheitis, 128–129
  in bronchiectasis, 281–282
  for bronchitis, 127
  for child with asthma, 210–215
nursing care (cont’d)
of child with FBA, 292
in cystic fibrosis, 235–241, 240
in epiglottitis, 162
for infant with BPD, 97–104
in obstructive sleep apnea, 263–265
in pneumonia, 124
in pneumothorax, 299–300
in primary ciliary dyskinesia, 278–279
in respiratory failure, 308
for rhinitis, 180
in sinusitis, 172–173
for tracheomalacia, 156–157
nutrition. See also feeding
in BPD, 97
in cystic fibrosis, 233
for infants with BPD, 102

obesity
and apnea incidence, 248
and OSA, 261
obstructive sleep apnea (OSA), 247
complications of, 256–258
daytime symptoms of, 264
diagnosis of, 254–256
epidemiology of, 248–249
management of, 258
medical history in, 252
morbidity associated with, 247
nursing care in, 263–265
pathophysiology of, 249–254
risk of, 248–249
signs and symptoms of, 250–254
syndrome of, 249
treatment for, 252
omalizumab
adverse effects associated with, 65
in asthma, 205
formulations for, 65
generic and brand names for, 65
indications for, 64–65
mechanism of action for, 64
oral decongestants, for sinusitis, 169
orbit, subperiosteal abscess of, 171
oropharynx, anatomy of, 133
osmotic agents, in cystic fibrosis, 234
osteopenia/osteoporosis, in CF population, 227
ostial obstruction, 164
otitis media, PCD associated with, 278
otolaryngological treatment, for PCD, 278
otorrhea, PCD associated with, 278
outdoor allergens, and asthma symptoms, 204
oxygen
carrying capacity for, 15–16
diffusion through air-blood barrier of, 11–12
perfusion limited transfer of, 12, 14
oxygen, supplemental
administration of, 99–100
in BPD, 96
in bronchiolitis, 117
injury induced by, 92–93
in pneumonia, 123
in pneumothorax, 298, 299
in respiratory failure, 306
oxygenation, assessment of, 195
oxygen-hemoglobin dissociation curve, 16, 16–19, 18, 19, 19, 20
oxygen saturation
optimal, 99–100
in respiratory failure, 304–305
oxyhemoglobin, in gas exchange, 15–19, 16, 18–20

pain
omalizumab associated with, 65
in pneumothorax, 295, 300
palivizumab (Synagis®)
in BPD, 97
for bronchiolitis, 115
for infants with BPD, 102
palpation, in respiratory physical examination, 46–48
pancreatic enzyme replacement therapy (PERT), in cystic fibrosis, 232
pancreatic insufficiency, in cystic fibrosis, 223
paradoxical vocal fold motion (PVFM), 145
parainfluenza, management of, 112–113
parainfluenza viruses, in laryngotracheobronchitis, 157
parasitic infections, omalizumab associated with, 65
parenchyma, transfer of gases in, 11–15, 13
parental care
   for child with epiglottitis, 162
   of infants with BPD, 102, 103, 104
   in laryngeal and tracheal conditions, 156
   in pneumonia, 124
parents, teaching. See also education
   about asthma, 210–211
   about chronic sinusitis, 173
   about epiglottitis, 162
partial pressure of carbon monoxide (PCO), 14
partial pressure of oxygen (PO₂)
   at birth, 6
   at sea level, 13, 13
PCO₂ changes in, 24
   and Henderson-Hasselbach equation, 22–23
peak expiratory flow (PEF), 79
peak flow meters, 79, 207–208
pectus excavatum, OSA and, 253
percussion
   defined, 48
   in respiratory physical examination, 48–49, 49
percussion sounds, 49, 49
percutaneous testing, for rhinitis, 177
performance objectives
   respiratory health, 241–242
   tracking form for, 242, 242–243
PERFs
   in asthma action plan, 213
   in exacerbations of asthma, 209
   measurement of, 208
perfusion
   in asthma, 193
   in disease states, 12
pertussis, immunization for, 127
pet dander, and asthma symptoms, 204
pets, and allergic rhinitis, 174
pH
   in oxygen-hemoglobin dissociation curve, 18
   in respiratory system, 22
PHACES syndrome, 153
pharyngomalacia, in OSA, 261
physical examination, 43
   in asthma, 195
   auscultation in, 48
   and child’s developmental level, 38–39
   in foreign body aspiration, 288–289
   inspection component of, 43, 44, 45–46, 46
palpation in, 46–48
percussion in, 48–49, 49
   in pneumothorax, 295–296
   in respiratory failure, 303
pigeon chest, Pectus carinatum, 43
placenta, as source of oxygen, 6
pleural effusion, 121
   confirmation of, 122
   defined, 122
pleurodesis, in pneumothorax, 298
pneumonia, 110
   adenoviral, 113
   aspiration, 122
   complications from, 121
pneumonia (cont’d)
in cystic fibrosis, 223
diagnosis of, 121
epidemiology of, 119
in FBA, 290, 291
management of, 123–124
nursing care in, 124
pathophysiology of, 119–121
PCD associated with, 272
recurrent, 124
signs and symptoms of, 120–121
pneumopericardium, asthma
associated with, 203
pneumothorax, 123, 292–293
asthma associated with, 203
complications of, 296
in cystic fibrosis, 226
diagnosis in, 296
epidemiology of, 293–294
management of, 296–299
nursing care for, 299–300
palpation in, 47
pathophysiology of, 294
primary and secondary, 292–293
recurrence of, 296
risk factors for, 293, 294
secondary, 294
signs and symptoms of, 295–296
spontaneous, 295, 299
tension, 295, 296, 300
pollens, in allergic rhinitis, 176
polycythemia, and alveolar
surface, 15
polyps
antrochoanal, 172
nasal, 172
polysomnography, 87
positioning
in airway obstruction, 138
in respiratory distress, 162
and worsening sleep apnea, 259–260
positive end expiratory pressure
(PEEP), in ARDS, 123
positive expiratory pressure (PEP)
for airway clearance, 276
in cystic fibrosis, 230–231
positive pressure ventilation
in BPD, 95
for oxygen administration, 100
postbronchodilator test, 196
Poussuille’s law, 135
preeclampsia, maternal, and
development of BPD, 92
premature stopcodon (PTC), 234
prematurity
apnea of, 86–91
retinopathy of, 99
prenatal care, in BPD, 98
pressure support (PS), for
mechanical ventilation, 307
preterm birth, complications
associated with, 100
primary ciliary dyskinesia (PCD)
complications of, 274–275
daily treatment regimens for, 278
defined, 269
diagnosis of, 273–274
epidemiology of, 270
management of, 275
airway clearance, 276–277
pharmacological treatment,
275–276
nursing care in, 278–279
pathophysiology of, 270–272,
271
phenotypes, 270
signs and symptoms of, 272
sources of information for, 279
promethazine, 68
propanolol, for children with
hemangiomas, 154
proton pump inhibitors, in cystic
fibrosis, 233
pseudoephedrine/
phenylpropanoamine
hydrochloride, for sinusitis,
169
psychological disorders, asthma
associated with, 203
pulmonary edema, 264
pulmonary function tests
in asthma, 197
development of, 14
pulmonary hypertension, in infants with BPD, 96
pulmonary parenchyma, 11
Pulmozyme® (rhDNAase), 276
pulse oximetry, 94
in pneumothorax, 300
in respiratory failure, 304, 308
quantitative pilocarpine
iontophoresis sweat test, in cystic fibrosis, 224–225
racemic epinephrine, for child with croup, 160
radioallergosorbent tests (RASTs), 177, 202
radiological evaluation, 150. See also chest X-ray
in bronchiectasis, 280
epiglottitis on, 161
in foreign body aspiration, 289–290, 290, 291
in PCD, 277
of pediatric airway, 138–139
in respiratory failure, 305–306
rapid maxillary expansion (RME), for children with OSA, 260
recurrent laryngeal nerve, 134
recurrent respiratory papillomatosis (RRP), 147–148
red blood cells, transport of gas in carboxyhemoglobin, 19–22, 21
oxyhemoglobin, 15–19, 16, 18–20
referrals, for CF child, 238
regulated upon activation normal T-cell expressed and secreted (RANTES), in asthma, 193
rehospitalization, risk for, 95, 104
REM sleep, 249, 255
residual volume, 26, 27
respiration
gas exchange during, 19–21, 21
normal, 25
termiology of, 26
respiratory acidosis, 23
respiratory alkalosis, 23
respiratory center, areas of, 35, 35
respiratory cilium, 270, 271
respiratory compensation, 24
respiratory distress syndrome (RDS)
genetic predisposition to, 92
in infants, 85
in neonates, 30, 92
respiratory equipment, cleaning and disinfecting, 237
respiratory failure, 300–301
acute, 301
in bronchiolitis, 116
causes of, 302
chronic, 306
complications of, 306
defined, 301
diagnosis of, 304–306
epidemiology of, 301, 302
management of, 306–308
nursing care in, 308
pathophysiology of, 301–303
prolonged, undetected, 303–304
signs and symptoms of, 209, 303–304, 308
respiratory health performance objectives, 241–242
respiratory insufficiency, chronic, 301
respiratory patterns, 45, 46
respiratory rate, 45
respiratory syncytial virus (RSV), 95, 110
diagnosis of, 112
evidence of, 111–112
mechanical ventilation in, 112
respiratory system anatomy of
embryology, 3–4, 5, 6, 7–8
pulmonary vascular development, 6–7, 8, 9
managing infection of, 241
retinopathy of prematurity (ROP), and oxygen saturation, 99
retractions, 45
  in airway obstruction, 137
  in respiratory distress, 162
  in respiratory failure, 304
reversibility testing, in asthma, 196
review of systems, head-to-toe, 42
rhinitis, 162, 173–174
  atrophic, 174
  causes of
    anatomical, 175
    nonanatomical, 174–175
  complications of, 180
  diagnosis of, 177–178
  epidemiology of, 176
gustatory, 178
hormonal, 176
infectious, 174–175, 176
management of
  environmental avoidance
    strategies, 178
  immunotherapy, 180
  pharmacological, 178–179
nursing care of, 180
pathophysiology of, 176
perennial allergic, 174
seasonal allergic, 173
signs and symptoms of, 176–177
tumors and, 175
vasomotor, 178
rhinitis, allergic, 173, 176, 177, 178
  and etiology of sinusitis, 165
  leukotriene modifiers for, 62
  rhinitis medicamentosa, 174, 178
rhinoscopy, to diagnose sinusitis, 167
rhinosinusitis, use of term, 163
saline, hypertonic
  in cystic fibrosis, 228
  in PCD patients, 277
  saline irrigations, for sinusitis, 168–169
  salmeterol, 54–55
Salmeterol Multicenter Asthma Research Trial, 55
scapular lines, 43, 44
school difficulties, of children with OSA, 258
school nurses, and pediatric OSA, 263
schools, support for children with asthma in, 214
screening
  for cystic fibrosis, 225
  for PCD, 275
secrections, in bronchitis, 126
self-management
  of asthma, 212–213
  objectives for CF patients and families in, 240–242
sepsis, 121–122
septic shock, 122
shortness of breath, in respiratory health history, 40–41
sickle cell disease, asthma associated with, 203
single-breath DLCO, 14–15
sinuses, anatomy of, 163
“sinus headache,” 166
sinusitis, 162
  and asthma symptoms, 207
  bacterial, 164
  categories of, 164
  chronic, 166
  complications of
    intracranial, 172
    orbital, 171
  definition of, 164
  diagnosis of, 166–167
  epidemiology of, 163–164
  management of
    acute, 167–168
    chronic sinusitis/recurrent sinusitis, 170
nursing care in, 172–173
otontogenic, 165
pathophysiology of, 164–165
signs and symptoms of, 165–166
supplemental therapies for, 168–170
surgical treatment for, 170–171
skin
assessment of, 45
effect of corticosteroids on, 60
skin testing, for rhinitis, 177
sleep
assessment of, 255
normal nighttime in children, 249
promotion of newborn, 101
sleep apnea, asthma associated with, 203. See also obstructive sleep apnea
sleep disorders, 263
sleep interview, 251
sleep labs, 254, 255
sleep studies
CPAP for, 262
expanded use of, 256
reasons for ordering, 255
smoking, maternal, and asthma incidence, 189
smoking exposure, and asthma symptoms, 204
smooth muscle, airway, pulmonary stretch receptors in, 33
snoring
hypertension associated with, 250
in pediatric population, 248
sodium channel blockers, in cystic fibrosis, 233–234
spacer devices
advantages of, 78
used with MDIs, 75
speech language pathologist (SLP), 146
sphenoid sinuses, 163
spirogram, of lung volumes and capacities, 27
spirometers, portable, 79
spirometry, in asthma
interpretation of, 197
performance, 196
spironolactone, 99
sputum production, in respiratory health history, 41
Staphylococcus aureus
in lower airway disease, 114, 114
MRSA, 129
pneumonia caused by, 120
steatorrhea, in cystic fibrosis, 223
steeple sign, in laryngotracheobronchitis, 158, 159
steroid resistance, in African Americans, 189
steroids
in children with croup, 159
in chronic sinusitis, 170
in exacerbations of asthma, 209
in hemangiomas, 154
in OSA, 260
for rhinitis, 179
topical nasal, 169
Streptococcus pneumoniae
in acute sinusitis, 164–165
in lower airway disease, 114, 114
pneumonia caused by, 120
stridor/stertor
in airway obstruction, 136–137, 137
congenital, 136
in foreign body aspiration, 289
in respiratory distress, 162
in respiratory failure, 304
in respiratory health history, 42
subglottic stenosis, 100–101
classification of, 150, 151
complications of, 151
diagnosis of, 149–150, 150, 151
epidemiology of, 148
grade III, 150, 151
management of, 150–151
pathophysiology of, 149
signs and symptoms of, 149
subglottis
anatomy of, 132
in laryngotraceobronchitis, 158
sudden infant death syndrome (SIDS), 86, 88
supraglottis, 132
supraglottitis. See epiglottitis
supraglottoplasty, in laryngomalacia, 141
surface, lung, 29
surfactant deficiencies, inheritance of, 31
surfactants
administration of, 98
during delivery, 4, 6
embryology of, 4, 30
proteins of, 30
in respiratory distress syndrome, 308
surgery
in PCD, 277
for pneumothorax, 299
for subglottic stenosis, 151
for VCP, 144
VCP secondary to, 143
sweat chloride testing, in cystic fibrosis, 224–225
sweating, during sleep, 251
synchronized intermittent mechanical ventilation (SIMV), 307
systemic inflammatory response syndrome (SIRS), 121–122
tartrazine, sensitivity to, 66
teaching. See also nursing care
about asthma, 210–211
about bronchiolitis, 118
about bronchitis, 127
about cystic fibrosis, 239–241, 240
about laryngeal and tracheal conditions, 156–158
about PCD, 279
about pneumonia, 124
about sinusitis, 173
team
CF care, 243
for child with respiratory failure, 309
temperature changes, and oxygen-hemoglobin dissociation curves, 19
“tennis ball technique,” in OSA, 259
tension pneumothorax, 295, 296, 300
theophylline
for apnea of prematurity, 90, 91
side effects of, 91
thoracentesis, indication for, 123
thoracoscopic treatment, of spontaneous pneumothorax, 299
thoracostomy, 298
thoracotomy, 299
tiotropium, 57
TOBI, 73
Tobi®, for PCD, 275–276
tobramycin, 71–72, 73, 275–276
tonsils, assessment of, 252–253
total lung capacity (TLC), 26, 27
trachea
anatomy of, 133
branching of airways from, 8
physiology of, 135
tracheomalacia, 155–157
tubular fluid dynamics of, 135, 135
tracheal abnormalities, in infants with BPD, 95
tracheal position, palpation for, 47
tracheitis. See bacterial tracheitis
tracheobronchial tree, in pulmonary vascular development, 6–7, 8, 9
tracheomalacia
diagnosis of, 155–156
epidemiology of, 155
management of, 156
nursing care of, 156–157
in OSA, 261
pathophysiology of, 155
signs and symptoms of, 155
tracheostomy
  in BPD, 96
  with laryngeal web, 152
  for oxygen administration, 100
  in subglottic hemangioma, 154
  in subglottic stenosis, 148, 151
  in VCP, 144
tracheostomy care, 100
tracheotomy, in laryngomalacia, 141
transient tachypnea of newborn, 293
transplantation, lung, in PCD, 277–278
transthoracic electrical impedance, 88
trauma
  and subglottic stenosis, 149
  VCP associated with birth, 142–143
tripod position, in epiglottitis, 161
Tucson Children’s Respiratory Study, 190
turbinates, 163
unified airway model, 180
vaccine
  Hib, 120, 160
  influenza, 102, 113
valved holding chambers (VHCs)
  advantages of, 78
  used with MDIs, 75
vaponephrine, nebulized, for child
  with croup, 160
ventilation
  in asthma, 193
  control of, 32–33, 34, 35–36
  dynamics of, 26, 27
  minute, 303
  pulmonary, 25, 25
ventilation, mechanical
  injury caused by, 93
  in respiratory failure, 307
  in RSV, 112
ventriculoperitoneal shunt, 144
vertebral line, 43, 44
very low birth weight (VLBW)
  infants, positioning of, 98
vesicular sounds, 48
vest therapy, for airway clearance, 276
video-assisted thoracoscopic surgery (VATS), 122, 299
video stoboscopy, 139
viral agents
  adenovirus, 113
  in bronchitis, 126
  human metapneumovirus, 114
  in influenza, 112
  in lower airway disease, 110–111
  in parainfluenza, 112
  in RSV, 111–112
viral infections, 111
  asthma associated with, 203
  and bacterial sinuses, 164
vital capacity (VC), 26, 27
vitamin A deficiency, in cystic fibrosis, 223
vitamin D deficiency, in cystic fibrosis, 223
vitamin E deficiency, in cystic fibrosis, 223
vitamin K deficiency, in cystic fibrosis, 224
vocal cord disorders, 141–142
  complications of, 146
  diagnosis of, 146, 194
  epidemiology of, 145
  exercise-induced, 145, 146
  management of, 146
  pathophysiology of, 145
  in psychiatric disease, 145
  signs and symptoms of, 145–146
vocal cord paralysis (VCP), 142
  complications of, 145
  diagnosis of, 143–144
  epidemiology of, 142
vocal cord paralysis (VCP) (cont’d)
management of, 144
pathophysiology of, 142–143
signs and symptoms of, 143
vocal cords
masses and lesions of, 146
nodules, 147
recurrent respiratory
papillomatosis of, 147–148
vocal fold immobility (VFI), 141–142, 144
vocalization, 134
vocal resonance, 49
voice, in airway obstruction, 137, 137–138
V/Q ratio, in hypoxemia, 302

wall suction, 299
Web sites, for PCD, 279

weight, in BPD, 101
weight loss, and OSA, 261
well child visits, asking about
  snoring during, 264
wheezing
  in asthma, 190
  in cystic fibrosis, 223, 226
  episodes of, 125
  in foreign body aspiration, 288
  in respiratory distress, 162
  in respiratory failure, 304
  in respiratory health history, 40
  in tracheomalacia, 155
World Health Organization (WHO), 119
zafirlukast (Accolate), 61, 63
zileuton (Zyflo), 63